Related Experiment Video

Updated: May 27, 2026

Precision Cut Lung Slices as an Efficient Tool for Ex vivo Pulmonary Vessel Structure and Contractility Studies
09:08

Precision Cut Lung Slices as an Efficient Tool for Ex vivo Pulmonary Vessel Structure and Contractility Studies

Published on: May 24, 2021

Endothelin receptor antagonists -- their role in pulmonary medicine

S Boniface1, M Reynaud-Gaubert

  • 1Cabinet de Pneumologie, 4, avenue de Delphes, 13006 Marseille, France.

Revue Des Maladies Respiratoires
|November 22, 2011
PubMed

Insights

Endothelin-receptor antagonists (ERAs) are crucial for treating pulmonary arterial hypertension (PAH). These drugs, targeting endothelin-1, show promise for other lung disorders, though further research is needed.

Area of Science:

  • Cardiovascular Medicine
  • Pulmonology
  • Pharmacology

Background:

  • Endothelin-1 (ET-1) is integral to endothelial disease pathophysiology, particularly pulmonary arterial hypertension (PAH).
  • This understanding led to the development of endothelin-receptor antagonists (ERAs), now central to PAH treatment.
  • Three ERAs (bosentan, sitaxentan, ambrisentan) are approved for PAH in France, with proven efficacy and safety.

Purpose of the Study:

  • To review the role of endothelin-1 in PAH.
  • To discuss the clinical application and potential of ERAs in managing pulmonary vascular diseases.
  • To explore emerging therapeutic uses of ERAs in other pulmonary conditions.

Main Methods:

  • Literature review of randomized clinical trials on ERAs in PAH.
  • Analysis of endothelin-1's function in endothelial cell proliferation and apoptosis.
  • Evaluation of preliminary data for ERAs in idiopathic pulmonary fibrosis and systemic sclerosis.

Main Results:

  • ERAs are established treatments for pulmonary arterial hypertension.
  • Endothelin-1 influences cell proliferation and apoptosis, beyond its vasoconstrictor effects.
  • Current data on ERAs for idiopathic pulmonary fibrosis and systemic sclerosis are insufficient or controversial.

Conclusions:

  • Endothelin-receptor antagonists are vital in managing pulmonary vascular diseases like PAH.
  • ERAs represent innovative therapies with potential applications in other pulmonary disorders.
  • Further investigation is required to validate ERAs for conditions such as idiopathic pulmonary fibrosis and systemic sclerosis.
Abstract

More Related Videos

Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension09:23

Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension

Published on: February 11, 2017

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...